Find out more about who we are, what we do and the people behind Epitopea.
Find out what makes us unique and the work we do with our revolutionary new platform.
All the latest company news, press releases and updates from Epitopea.
We Are Epitopea

Revealing the true targets for next generation immunotherapies

We believe better cancer therapies are needed to transform people’s lives. We are developing accessible off-the-shelf cancer immunotherapies that will deliver durable benefits.

We Are Epitopea

We believe better cancer therapies are needed to transform people’s lives. We are developing accessible off-the-shelf cancer immunotherapies that will deliver durable benefits.
Learn more
We are a global leader in exploiting a novel class of untapped tumour-specific antigens (TSAs), CryptigenTM TSAs, designed to treat a broad patient population.
Epitopea is a transatlantic cancer immunotherapeutics company based in Montreal, Canada and Cambridge, UK.

Our technology platform builds on our proprietary and innovative approach to identifying shared, aberrantly expressed tumour-specific antigens (aeTSA), known as CryptigenTM TSAs, which we have exclusively licensed from the Université de Montréal (UdeM), along with the rights to exploit large sets of CryptigenTM TSAs in solid and hematological cancers.

Latest News

Epitopea Featured in BioWorld

Date: May 11, 2022 |
Epitopea closes $14M seed round for tumor antigen discovery Epitopea Ltd. raised $13.6 million in seed financing to take forward […]
Read More

Epitopea Announces $14 Million Financing to Advance Cancer Immunotherapeutics

Date: April 25, 2022 |
Novel CryptigenTM technology unlocks full potential of Tumour Specific Antigens CAMBRIDGE, UK and MONTREAL, CANADA, 25 April 2022 - Epitopea, […]
Read More

BioTrinity 2022: 26th & 27th April 2022

Date: April 4, 2022 |
Epitopea will be attending BioTrinity 2022 from the 26th to 27th April 2022. BioTrinity is an established, must-attend London conference, […]
Read More
Revealing the true targets for next generation immunotherapies
© 2022 Epitopea Ltd | All Rights Reserved
Created by FDM Digital